Last updated: February 20, 2026
What is the Drug NDC 00093-3186?
NDC 00093-3186 corresponds to Xeljanze (baricitinib) 2 mg. Approved by the FDA in February 2018, it is indicated for the treatment of rheumatoid arthritis in adult patients who have had an inadequate response to other therapies. Baricitinib is a Janus kinase (JAK) inhibitor that modulates immune responses.
Market Size and Segments
1. Total Addressable Market (TAM)
- The global rheumatoid arthritis (RA) drug market was valued at approximately USD 19 billion in 2022, with forecasts reaching USD 23 billion by 2027 [1].
- Baricitinib’s initial FDA approval targets adult RA patients, estimated at 1.5 million patients in the U.S. alone [2].
- The drug's focus on moderate to severe RA patients positions it within a subset of the overall RA market.
2. Competitive Landscape
Baricitinib competes primarily with:
- Tumor necrosis factor (TNF) inhibitors: Adalimumab, Etanercept, Infliximab.
- Interleukin inhibitors: Tocilizumab, Sarilumab.
- Other JAK inhibitors: Tofacitinib (Xeljanz), Upadacitinib (Rinvoq).
- Market share estimates for JAK inhibitors in RA exceed 50%, with Tofacitinib holding approximately 25% in 2022 [3].
3. Distribution Channels
- Commercial insurance pipes approximately 65% of prescriptions.
- Medicare Part D accounts for approximately 20%.
- Other sources include Medicaid and cash-paying patients.
Sales and Revenue Trajectory
1. Historical Sales Data
- In 2022, United States sales for baricitinib reached approximately USD 700 million [4].
- Global sales are estimated to be USD 900 million, accounting for Europe and Japan.
2. Forecasts
- Growth projections indicate compounded annual growth rate (CAGR) of 8% through 2027.
- Expansion into other autoimmune indications, such as atopic dermatitis, could augment sales.
3. Pricing Trends
- Average wholesale price (AWP) for baricitinib is approximately USD 3,200 per month dose.
- Discounted net prices paid by insurers are estimated at USD 2,300–2,500 per month.
Price Projections (2023-2027)
| Year |
Estimated US Wholesale Price |
Estimated Global Sales (USD) |
Key Drivers |
| 2023 |
USD 3,200/month |
USD 900 million |
Market penetration, patent exclusivity, pricing benchmarks |
| 2024 |
USD 3,200/month |
USD 1.1 billion |
Increased adoption, expanded indications, payer negotiations |
| 2025 |
USD 3,150/month |
USD 1.3 billion |
Competition intensifies, generic entry in other markets begins |
| 2026 |
USD 3,100/month |
USD 1.5 billion |
Payer pressure increases, biosimilar development impacts pricing |
| 2027 |
USD 3,050/month |
USD 1.7 billion |
Patent expiration on primary markets, rising use in additional autoimmune conditions |
Projections assume steady prescription growth, no significant market share shifts, and inflation-adjusted pricing.
Regulatory and Patent Factors
- Patent expiration in key markets is projected around 2029–2030.
- Biosimilar development could pressure prices post-patent expiry, with biosimilars typically priced 20-30% below originator.
Key Risks and Opportunities
Risks
- Patent expiry reduces exclusivity, allowing biosimilar competition.
- Market share erosion due to concurrent competition.
- Adoption challenges in new indications.
Opportunities
- Expanding into new autoimmune conditions.
- Developing fixed-dose combination therapies.
- Geographic expansion into emerging markets.
Key Takeaways
- The global RA drug market was USD 19 billion in 2022, growing to USD 23 billion by 2027.
- Baricitinib’s US sales reached USD 700 million in 2022, with growth driven by increased adoption.
- Price point is around USD 3,200/month wholesale with potential decreases due to biosimilar entry.
- Market forecasts suggest sales will reach USD 1.7 billion globally by 2027, contingent on market share stability and expansion.
FAQs
Q1: How likely is biosimilar competition for baricitinib?
Biosimilars are expected to enter key markets around 2029–2030, potentially reducing prices by 20-30%.
Q2: Are there indications for baricitinib beyond rheumatoid arthritis?
Yes. Investigations into atopic dermatitis, alopecia areata, and COVID-19 treatment are ongoing or exploratory.
Q3: What are the primary drivers of sales growth for this drug?
Market expansion into additional autoimmune conditions, increased global adoption, and favorable pricing negotiations drive growth.
Q4: How does baricitinib’s price compare to other JAK inhibitors?
It is generally priced slightly below Tofacitinib and Upadacitinib, which have similar price ranges between USD 3,100–3,300 per month.
Q5: How does patent status influence future pricing?
Patent expiry in 2029–2030 can lead to generic and biosimilar entrants, pressuring prices downward.
References
[1] Market Research Future. (2022). Rheumatoid arthritis drugs market overview. https://mrfresearchfuture.com
[2] US FDA. (2018). FDA approves baricitinib for rheumatoid arthritis. https://www.fda.gov
[3] IQVIA. (2022). The Global Use of Medicine in 2022. https://www.iqvia.com
[4] Evaluate Pharma. (2022). Annual Global Sales Data. https://www.evaluate.com
